68,562 Shares in Amgen Inc. $AMGN Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 68,562 shares of the medical research company’s stock, valued at approximately $22,441,000. Amgen comprises approximately 0.8% of Fideuram Intesa Sanpaolo Private Banking S.P.A.’s investment portfolio, making the stock its 25th largest holding.

Several other institutional investors have also recently made changes to their positions in AMGN. Capital World Investors raised its stake in Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares during the period. Vanguard Group Inc. raised its stake in Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the period. National Bank of Canada FI raised its stake in shares of Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after acquiring an additional 863,216 shares during the period. Van ECK Associates Corp lifted its holdings in shares of Amgen by 71.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock worth $383,254,000 after acquiring an additional 567,400 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in shares of Amgen by 91.6% in the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock worth $221,607,000 after acquiring an additional 375,463 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.85% of the stock is currently owned by insiders.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a planned CFO transition, with Peter Griffith retiring and Thomas Dittrich returning to the company to succeed him. A well-telegraphed succession plan can reduce uncertainty around finance leadership and is typically viewed as a stability signal. AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
• Neutral Sentiment: Amgen also named an analyst report in the news flow, along with Piper Sandler trimming its price target while keeping an Overweight rating. That suggests continued long-term optimism, but the target cut is a modest headwind rather than a major catalyst. Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism
• Negative Sentiment: Separately, Amgen’s kidney disease drug Tavneos faced renewed scrutiny in Japan, where partner Kissei urged doctors to use caution and avoid starting new patients amid safety and regulatory concerns. Headlines like this can pressure sentiment because they raise questions about the product’s commercial trajectory and safety profile. Amgen Japanese Partner Urges Caution On Tavneos Use

Wall Street Analyst Weigh In

AMGN has been the topic of several recent analyst reports. Citigroup upped their price objective on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Argus upped their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective on the stock. in a report on Tuesday, January 20th. Finally, Leerink Partners restated a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $356.15.

Amgen Price Performance

Shares of AMGN opened at $330.75 on Wednesday. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The firm’s 50 day moving average price is $347.53 and its 200 day moving average price is $343.86. The company has a market cap of $178.50 billion, a P/E ratio of 23.02, a PEG ratio of 3.26 and a beta of 0.44. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the prior year, the firm earned $4.90 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts forecast that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.15%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.